创下新高!一款国产减肥药卖了20亿美元

界面
25 Mar

界面新闻记者 |陈杨界面新闻编辑 |谢欣当下最火热的降糖减重领域又现重磅交易。3月24日晚间,国内药企联邦制药宣布与跨国药企诺和诺德签订独家许可协议。后者将获得前者三靶点GLP-1药物UBT251在海外的开发、制造和商业化权益。根据协议,联邦制药将有资格获得2亿美元预付款、最高18亿美元的潜在里程碑付款,及相应分层销售提成。不过3月25日开盘,联邦制药股价一路大跌,收盘价报14.680港元/股,跌...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10